Health Care [ 12/12 ] | Pharmaceuticals [ 64/74 ]
NYSE | Common Stock
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide.
The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery.
It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics.
The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis.
Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 17, 24 | 2.82 Increased by +0.71% | 2.70 Increased by +4.44% |
| Apr 16, 24 | 2.71 Increased by +1.12% | 2.64 Increased by +2.65% |
| Jan 23, 24 | 2.29 Decreased by -2.55% | 2.28 Increased by +0.44% |
| Oct 17, 23 | 2.66 Increased by +4.31% | 2.52 Increased by +5.56% |
| Jul 20, 23 | 2.80 Increased by +8.11% | 2.62 Increased by +6.87% |
| Apr 18, 23 | 2.68 Increased by +0.37% | 2.50 Increased by +7.20% |
| Jan 24, 23 | 2.35 Increased by +10.33% | 2.23 Increased by +5.38% |
| Oct 18, 22 | 2.55 Decreased by -1.92% | 2.47 Increased by +3.24% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 22.47 B Increased by +5.25% | 2.69 B Decreased by -89.65% | Increased by +11.99% Decreased by -90.17% |
| Jun 30, 24 | 22.45 B Decreased by -12.13% | 4.69 B Decreased by -8.90% | Increased by +20.88% Increased by +3.67% |
| Mar 31, 24 | 21.38 B Decreased by -13.55% | 3.25 B Increased by +4.89 K% | Increased by +15.22% Increased by +5.64 K% |
| Dec 31, 23 | 21.39 B Decreased by -9.75% | 4.05 B Increased by +15.03% | Increased by +18.92% Increased by +27.45% |
| Sep 30, 23 | 21.35 B Decreased by -10.26% | 26.03 B Increased by +483.85% | Increased by +121.91% Increased by +550.57% |
| Jun 30, 23 | 25.55 B Increased by +6.35% | 5.14 B Increased by +6.86% | Increased by +20.14% Increased by +0.48% |
| Mar 31, 23 | 24.73 B Increased by +5.58% | -68.00 M Decreased by -101.32% | Decreased by -0.27% Decreased by -101.25% |
| Dec 31, 22 | 23.71 B Decreased by -4.43% | 3.52 B Decreased by -25.68% | Increased by +14.85% Decreased by -22.23% |